Table II.
Subgroup analysis for androgen receptor and clinicopathological features and prognosis in bladder cancer.
| Heterogeneity | ||||||
|---|---|---|---|---|---|---|
| Category | n | Odds ratio | 95% confidence interval | P-value | I-squared, % | P-value |
| Susceptibility due to ethnicity | ||||||
| Caucasian | 3 | 1.13 | 0.05–24.47 | 0.98 | 95.30 | <0.01 |
| Asian | 2 | 4.34 | 0.01–3544.09 | 0.66 | 95.10 | <0.01 |
| Tumor grade and ethnicity | ||||||
| Caucasian | 4 | 1.95 | 1.36–2.81 | <0.01 | 60.90 | 0.05 |
| Asian | 2 | 1.30 | 0.72–2.35 | 0.39 | 0 | 0.9 |
| Classification system | ||||||
| 2004 WHO | 4 | 1.94 | 1.35–2.80 | <0.01 | 11 | 0.34 |
| 1998 WHO | 2 | 1.25 | 0.68–2.32 | 0.47 | 72.80 | 0.05 |
| Tumor stage and ethnicity | ||||||
| Caucasian | 8 | 2.06 | 1.02–4.16 | 0.04 | 77 | <0.01 |
| Asian | 1 | 0.43 | 0.11–1.58 | 0.20 | NA | NA |
| Recurrence-free survival and ethnicity | ||||||
| Caucasian | 3 | 0.48a | 0.31–0.75 | 0.01 | 0 | 0.42 |
| Asian | 2 | 1.13a | 0.87–1.47 | 0.74 | 47.70 | 0.125 |
| Progression-free survival and ethnicity | ||||||
| Caucasian | 3 | 1.31a | 0.92–1.85 | 0.13 | 55 | 0.07 |
| Asian | 1 | 0.61a | 0.23–1.62 | 0.32 | NA | NA |
a
Indicates hazard ratio value. NA, not applicable.